Reviewed 31 August 2026. Sources: three Cochrane reviews (topical therapies, non-pharmacological interventions, and prevention of radiotherapy-related salivary dysfunction), two prevalence systematic reviews, one meta-analysis of pilocarpine, and three observational studies on root caries risk in older adults. Written for patients and for clinicians. Not medical advice.
Related on this site: fluoride varnish for children and SDF for root and cavity arrest — both are the tools that matter most once saliva is low.
The short answers
- Dry mouth is common and under-measured. A systematic review with meta-regression of 29 population studies estimated an overall prevalence of 22.0% (95% CI 17.0% to 26.0%), higher in studies of older people; an earlier review of thirteen population-based studies found a range from 0.9% to 64.8% — mostly Scandinavian samples, and none of them looked at anyone under 18 (Agostini et al., Braz Dent J 2018-11-01, PMID 30517485) (Orellana et al., J Public Health Dent 2006-01-01, PMID 16711637). That spread is itself the finding: how you ask determines the number.
- The causes most often cited in the clinical literature are medications, Sjögren’s syndrome, radiotherapy or chemotherapy for head and neck cancer, hormone disorders and infections (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442). For most people with the symptom, the explanation is in their prescription list.
- The dental consequence is specific and measurable: root caries. In a prospective longitudinal study of 334 independently living older adults (mean age 69.1 years), 53.3% already had at least one filled or decayed root surface, and in multivariate analysis xerostomia was associated with root caries at OR 18.49 (95% CI 2.00 to 172.80), poor plaque control at OR 9.59 (3.84 to 24.00), two or more teeth with coronal decay at OR 4.50 and 37 or more exposed root surfaces at OR 5.48 (Hayes et al., J Dent 2016-08-01, PMID 27208875). Read the interval, not just the point estimate: that xerostomia figure is enormous but imprecise, which is a fair description of the whole literature.
- What you put on the teeth matters more than what you put on the teeth to make them feel wet. The Cochrane review of topical therapies — 36 randomised trials, 1,597 participants, of which only one trial was at low risk of bias and 17 at high risk — concluded there is no strong evidence that any topical therapy relieves the symptom of dry mouth. The one exception it could quantify: an oxygenated glycerol triester spray beat an electrolyte spray (SMD 0.77, 95% CI 0.38 to 1.15), about two points on a 10-point scale (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
- Chewing gum does have a physiological role and no demonstrated supremacy: it increases saliva production in people with residual secretory capacity, but the review found no evidence that gum is better or worse than saliva substitutes (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442). Sugar-free, xylitol-containing gum is therefore a sensible mechanical trick — and nothing more than that.
Why low saliva is such a big dental problem
Saliva is not just moisture. It buffers the acid that plaque bacteria produce, it carries calcium and phosphate that stabilize early demineralisation, it has antimicrobial properties, and it physically clears food. Remove the flow and you do not simply get discomfort: you change the chemistry of every hour of the day. The decay that follows has a characteristic location — on the exposed root surfaces and around the necks of teeth, and around restorations — because that is the surface that relied on saliva rather than on enamel thickness. That is also why the pattern is different from the childhood caries story: here it is not primarily about sugar reaching a deep fissure, it is about acid surviving.
The older-adult risk data line up across three independent samples. In a national British survey of 462 dentate people aged 65 and over, nine or more sugar intakes per day more than doubled the odds of root caries (OR 2.2 to 2.4), infrequent brushing gave OR 2.8 to 4.1, and a partial denture worn with heavy plaque OR 2.1 to 2.6 — and among people who already had root caries, sucking sweets in the presence of a dry mouth was one of the factors that predicted how extensive it was (Steele et al., Gerodontology 2001-12-01, PMID 11794744). In a Japanese sample of 287 independently living people over 60, 39% had at least one decayed root and 53.3% had at least one decayed or filled root lesion; frequent brushing was associated with fewer decayed roots (P = 0.058) and low salivary flow or a subjective feeling of dryness with more (P = 0.059 and P = 0.052) (Imazato et al., J Oral Rehabil 2006-02-01, PMID 16457674). Three countries, three cross-sectional designs, the same short list of levers: frequency of sugar, mechanical cleaning, and flow.
What the Cochrane reviews found about treating the symptom
Topical therapies — lozenges, sprays, rinses, gels, oils, gums and toothpastes. Thirty-six trials, 1,597 participants; 2 trials compared stimulants with placebo, 9 substitutes with placebo, 5 stimulants directly with substitutes, 18 compared substitutes with each other. The overall verdict is not a marketing-friendly one: “There is no strong evidence from this review that any topical therapy is effective for relieving the symptom of dry mouth.” The oxygenated glycerol triester (OGT) spray outperformed an aqueous electrolyte spray by SMD 0.77 (95% CI 0.38 to 1.15) — roughly two points on a 10-point VAS. Integrated mouthcare systems and oral reservoir devices looked “promising” but were not sufficiently evidenced to recommend, and gum, while raising saliva where capacity remains, was not shown to beat substitutes (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442). The review’s closing sentence is the most useful line in the whole dry-mouth literature for a patient: well-designed, adequately powered trials, reported to CONSORT standards, are needed to guide care (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
Non-pharmacological methods — acupuncture and electrostimulation. Nine studies, 366 participants randomised; eight at high risk of bias in at least one domain. For acupuncture versus placebo after radiotherapy, two poolable trials (70 participants, low quality) found no difference in dry-mouth symptoms (SMD −0.34, 95% CI −0.81 to 0.14, p = 0.17), with mild transient adverse effects (bruising, tiredness); the flow measures showed tiny changes — unstimulated whole saliva up by an average of 0.02 ml/minute (95% CI 0 to 0.04) and, at 12 months, 0.06 ml/minute (0.01 to 0.11), stimulated saliva 0.19 ml/minute (0.07 to 0.31) — statistically positive, clinically small, and derived from samples of 54 to 71 people (Furness et al., Cochrane Database Syst Rev 2013-09-01, PMID 24006231). This is what “some evidence” actually looks like when you read the numbers instead of the abstract’s conclusion sentence.
After radiotherapy specifically, prevention has better data than symptom relief. A Cochrane review of pharmacological interventions to prevent radiation-induced salivary dysfunction included 39 studies and 3,520 participants, and reported low-quality evidence that amifostine may reduce the risk of moderate-to-severe xerostomia at the end of radiotherapy (RR 0.35, 95% CI 0.19 to 0.67; 3 studies, 119 participants) and up to three months after (RR 0.66, 95% CI 0.48 to 0.92; 5 studies, 687 participants), but the effect was not sustained at 12 months (RR 0.70, 95% CI 0.40 to 1.23; 7 studies, 682 participants) and there was insufficient evidence that it compromised cancer outcomes (Riley et al., Cochrane Database Syst Rev 2017-07-01, PMID 28759701). If you are about to start head and neck radiotherapy, that is a question for the oncology team before treatment begins — not after the mouth is already dry.
Sialogogues. A meta-analysis of pilocarpine in radiation-induced xerostomia identified six studies (752 patients) and, pooling three, found a mean difference in VAS dry-mouth score of 12.00 (95% CI 1.93 to 22.08, p = 0.02) in favour of pilocarpine, with more adverse events — sweating at OR 3.71 (95% CI 2.34 to 5.86) — and the authors noted that one of the three pooled studies had shown no effect; their practical suggestion was 5 mg three times daily, with more study needed (Cheng et al., J Am Dent Assoc 2016-04-01, PMID 26563850). Translation: there is a real, modest symptomatic benefit for people who retain some glandular function, paid for with sweating and other cholinergic effects, and it is a prescription decision (asthma, cardiac and eye conditions matter) rather than a supplement.
The part that is actually evidence-based: protecting the teeth
If the saliva will not come back, the dental plan does not consist of making the mouth feel wetter. It consists of changing what the plaque can do with what you eat, and giving the enamel more fluoride than a normal-risk mouth needs:
- Frequency of sugar and acid, not just amount. The British older-adult data are explicit about intakes per day, not grams per day (Steele et al., Gerodontology 2001-12-01, PMID 11794744).
- High-concentration fluoride toothpaste and/or professionally applied fluoride varnish, at intervals tied to your risk — the varnish evidence is decent in children (a 43% prevented fraction on permanent teeth) and thin in toddlers, which is a good honest note to read before anyone promises you a miracle here (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442). Where the ADA panel is explicit that prescription-strength home fluoride is a ≥6-years option, that is precisely the tool an adult with root exposure is discussing.
- Fluoride varnish and, for an arrested-but-visible root lesion, a caries-arresting medicament such as SDF, which has its own evidence and its own trade-off (permanently darkened lesion) — read that separately.
- Chewing sugar-free gum after meals where you still have gland capacity — a real effect on flow, without any claim that it outperforms substitutes (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
- A recall interval shorter than the standard six months, with radiographs that let the dentist see the root surfaces, because root caries near the gumline hides from a visual glance under a lip.
- Medication review with the prescriber. Not “stopping your medicines”, but asking whether an anticholinergic load can be reduced, a dose moved, or an alternative substituted. That is a physician’s call, and the dentist’s job is to raise it in writing.
Also worth naming: candidiasis. The radiotherapy literature lists it among the secondary consequences of salivary loss, together with difficulty chewing, swallowing and speaking, and a significant effect on quality of life (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442). Persistent soreness, altered taste or a burning mouth with a white coating is not “part of the dryness” and deserves treatment and reassessment.
Evidence at a glance
| Source | What it covered | Finding as reported | Caveat |
|---|---|---|---|
| Agostini et al. 2018 (Agostini et al., Braz Dent J 2018-11-01, PMID 30517485) | 29 population studies, meta-regression | Pooled dry-mouth prevalence 22.0% (95% CI 17.0–26.0%), higher in the elderly | Measurement methods “may over- or underestimate” |
| Orellana et al. 2006 (Orellana et al., J Public Health Dent 2006-01-01, PMID 16711637) | 13 population-based studies, self-reported diagnosis | Prevalence 0.9% to 64.8%; mostly Scandinavia; no study under 18 years | Questionnaire definitions varied |
| Cochrane: topical therapies (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442) | 36 RCTs, 1,597 participants | No strong evidence for any topical therapy; OGT spray vs electrolyte spray SMD 0.77 (0.38–1.15) ≈ 2 points on a 10-point VAS; gum raises flow but not proven superior | Only 1 trial at low risk of bias; 17 at high |
| Cochrane: non-pharmacological (Furness et al., Cochrane Database Syst Rev 2013-09-01, PMID 24006231) | 9 studies, 366 participants | Acupuncture vs placebo: no symptom difference (SMD −0.34, −0.81 to 0.14); saliva flow changes of 0.02–0.19 ml/min; mild adverse effects | 8 studies high risk of bias; samples of 54–71 |
| Cochrane: prevention after radiotherapy (Riley et al., Cochrane Database Syst Rev 2017-07-01, PMID 28759701) | 39 studies, 3,520 participants | Amifostine RR 0.35 (0.19–0.67) at end of RT; RR 0.66 (0.48–0.92) at ≤3 months; RR 0.70 (0.40–1.23) at 12 months | Low quality; effect not sustained |
| Pilocarpine meta-analysis (Cheng et al., J Am Dent Assoc 2016-04-01, PMID 26563850) | 6 studies, 752 patients (3 pooled) | VAS improvement MD 12.00 (1.93–22.08, p = 0.02); sweating OR 3.71 (2.34–5.86) | One of the three pooled studies showed no effect |
| Hayes et al. 2016 (Hayes et al., J Dent 2016-08-01, PMID 27208875) | 334 older adults, mean 69.1 y, prospective cohort | 53.3% with ≥1 filled/decayed root; xerostomia OR 18.49 (2.00–172.80); plaque control OR 9.59 (3.84–24.00); ≥37 exposed roots OR 5.48 | Huge intervals; single Irish cohort |
| Steele et al. 2001 (Steele et al., Gerodontology 2001-12-01, PMID 11794744) | 462 British adults 65+, national survey | ≥9 sugar intakes/day OR 2.2–2.4; infrequent brushing OR 2.8–4.1; partial denture + heavy plaque OR 2.1–2.6 | Cross-sectional |
| Imazato et al. 2006 (Imazato et al., J Oral Rehabil 2006-02-01, PMID 16457674) | 287 Japanese adults 60+ | 39% with ≥1 decayed root; more decayed roots with low salivary flow (P = 0.059) or perceived dryness (P = 0.052); fewer with frequent brushing (P = 0.058) | Selected community sample; P-values near threshold |
What to actually do: a seven-line plan
- Ask your prescriber for an anticholinergic and diuretic review. Bring the list, including eye drops and nasal sprays.
- Ask your dentist to record the root surfaces — number of exposed roots, plaque scores, and whether they can measure salivary flow — and to put the risk level in the notes. That record is also what gets a plan covered.
- Use high-concentration fluoride toothpaste (prescription strength) once a day at night, without rinsing afterwards, if your dentist agrees; add professionally applied varnish at recall.
- Change sugar from “how much” to “how often”, and stop the sipping pattern that keeps pH low all day (Steele et al., Gerodontology 2001-12-01, PMID 11794744).
- Sugar-free gum after meals if you still produce saliva; a substitute spray or gel if you do not (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
- Book a shorter recall interval, and keep the radiographs in the file so the next dentist sees the trajectory, not a snapshot.
- If you are starting head and neck radiotherapy: ask about amifostine, salivary-sparing technique and sialogogues before treatment (Riley et al., Cochrane Database Syst Rev 2017-07-01, PMID 28759701) (Cheng et al., J Am Dent Assoc 2016-04-01, PMID 26563850).
What the evidence does not support
- That any rinse, gel or lozenge is a proven treatment for the symptom. The Cochrane conclusion is explicitly the opposite, with 36 trials behind it (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
- That “dry mouth is just discomfort”: in older adults it sits in the same short list of risk factors as plaque control and exposed root surfaces for root caries (Hayes et al., J Dent 2016-08-01, PMID 27208875).
- That acupuncture is a proven fix: no symptom difference pooled, tiny flow changes, small high-risk-of-bias samples (Furness et al., Cochrane Database Syst Rev 2013-09-01, PMID 24006231).
- That amifostine is a durable protective: the benefit narrowed and lost significance by 12 months (Riley et al., Cochrane Database Syst Rev 2017-07-01, PMID 28759701).
- That prevalence numbers are comparable across studies. 0.9% to 64.8% in one review is a measurement artefact, not a geographic fact (Orellana et al., J Public Health Dent 2006-01-01, PMID 16711637).
Frequently asked questions
Can my blood pressure tablets or antidepressant do this? Yes — medications are at the top of the cause list in the clinical literature, and the review of topical therapies lists medications first (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442). Do not stop anything on your own; ask for a review with your prescriber.
What is the single most useful thing to change? Reduce how often sugar and acid hit the teeth, and get more fluoride onto the root surfaces. Saliva substitutes make the mouth feel better; they do not replace what saliva does chemically (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442) (Steele et al., Gerodontology 2001-12-01, PMID 11794744).
Do saliva substitutes work? One product (OGT spray) beat an electrolyte spray by about two points on a 10-point scale, and the review could not endorse the rest (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
Does chewing gum help? It increases flow if your glands still work, and it has not been shown to be better or worse than substitutes — so it is a reasonable habit, not a therapy (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
Is dry mouth going to give me cavities? It is one of the strongest associations reported in older adults — with the odds ratio for root caries around 18 in one cohort, though with a very imprecise interval (Hayes et al., J Dent 2016-08-01, PMID 27208875). “Strong association” is not “certain”, and it is definitely a reason for a shorter recall and higher fluoride rather than for panic.
Pilocarpine — should I ask for it? If you have residual gland function, there is modest symptomatic evidence for it and a real side-effect cost (sweating OR 3.71); the dose in the reviewed literature was 5 mg three times daily and it is a prescription with contraindications (Cheng et al., J Am Dent Assoc 2016-04-01, PMID 26563850).
I had radiotherapy and my mouth has been dry for years. Any point? The preventive drugs and amifostine data are about prevention around treatment, so for established dryness the plan is fluoride, recall, sugar frequency, and symptom management — plus treatment for candidiasis if present (Riley et al., Cochrane Database Syst Rev 2017-07-01, PMID 28759701) (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
My partner’s mouth is dry only at night. Night-time dryness is often mouth-breathing, snoring or a bedroom that is too dry, and it still matters for the front teeth. It is a different problem from drug-induced hyposalivation — worth mentioning to the dentist, because the pattern changes which surfaces to protect.
Glossary
- xerostomia ↔ the subjective feeling of dry mouth; salivary gland hypofunction ↔ measured low flow. They do not always travel together, which is why prevalence estimates vary so much (Agostini et al., Braz Dent J 2018-11-01, PMID 30517485).
- anticholinergic ↔ the drug class most associated with dryness (some bladder, allergy, sleep, antidepressant and Parkinson’s medicines); a review question, not an auto-stop.
- root caries ↔ decay on exposed root surfaces; the dental consequence that makes dry mouth a disease rather than a nuisance.
- sialogogue ↔ a drug that drives saliva out of remaining functioning glands (pilocarpine, cevimeline) — useless if there is nothing left to stimulate.
- amifostine ↔ a cytoprotective agent given around radiotherapy, with a time-limited benefit in the reviewed evidence (Riley et al., Cochrane Database Syst Rev 2017-07-01, PMID 28759701).
- OGT ↔ oxygenated glycerol triester spray, the one topical product with a quantified advantage in the Cochrane review (Furness et al., Cochrane Database Syst Rev 2011-12-01, PMID 22161442).
How this page was built, and what it cannot tell you
The structure follows the evidence: prevalence first (because the numbers disagree), then the symptom-treatment reviews (because that is what patients are sold), then the risk studies (because that is what actually damages teeth), then the plan. Bibliographic details for each item below were retrieved and verified programmatically from Europe PMC. Where an effect estimate could not be verified from the source, it is not stated.
What it cannot tell you: whether your own flow is low or your sensation is heightened (that needs measurement), which of your medicines is responsible, whether your root surfaces are already demineralising, and how much fluoride you personally need. Those are answered by a dentist with a probe, a chart and radiographs — plus a prescriber who is willing to look at the list.
This article summarises published research for information only. It is not medical or dental advice and does not replace assessment by a licensed dentist or physician. Do not stop or change prescribed medication on the basis of this page; seek prompt care for facial swelling, fever, a painful tooth, or white patches and burning that do not settle.
Sources
Peer-reviewed evidence
- Agostini BA, Cericato GO, Silveira ERD, Nascimento GG, Costa FDS, Thomson WM, Demarco FF. How Common is Dry Mouth? Systematic Review and Meta-Regression Analysis of Prevalence Estimates. Braz Dent J 2018-11-01;29(6):606-618. doi:10.1590/0103-6440201802302 · PMID 30517485 · cited by 93 (Europe PMC)
- Orellana MF, Lagravère MO, Boychuk DG, Major PW, Flores-Mir C. Prevalence of xerostomia in population-based samples: a systematic review. J Public Health Dent 2006-01-01;66(2):152-158. doi:10.1111/j.1752-7325.2006.tb02572.x · PMID 16711637 · cited by 108 (Europe PMC)
- Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011-12-01;:CD008934. doi:10.1002/14651858.cd008934.pub2 · PMID 22161442 · PMCID PMC13266506 · cited by 108 (Europe PMC)
- Furness S, Bryan G, McMillan R, Birchenough S, Worthington HV. Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 2013-09-01;:CD009603. doi:10.1002/14651858.cd009603.pub3 · PMID 24006231 · PMCID PMC7100870 · cited by 38 (Europe PMC)
- Riley P, Glenny AM, Hua F, Worthington HV. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database Syst Rev 2017-07-01;7():CD012744. doi:10.1002/14651858.cd012744 · PMID 28759701 · PMCID PMC6483146 · cited by 57 (Europe PMC)
- Cheng CQ, Xu H, Liu L, Wang RN, Liu YT, Li J, Zhou XK. Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: A systematic review and meta-analysis. J Am Dent Assoc 2016-04-01;147(4):236-243. doi:10.1016/j.adaj.2015.09.014 · PMID 26563850 · cited by 34 (Europe PMC)
- Hayes M, Da Mata C, Cole M, McKenna G, Burke F, Allen PF. Risk indicators associated with root caries in independently living older adults. J Dent 2016-08-01;51():8-14. doi:10.1016/j.jdent.2016.05.006 · PMID 27208875 · cited by 68 (Europe PMC)
- Steele JG, Sheiham A, Marcenes W, Fay N, Walls AW. Clinical and behavioural risk indicators for root caries in older people. Gerodontology 2001-12-01;18(2):95-101. doi:10.1111/j.1741-2358.2001.00095.x · PMID 11794744 · cited by 62 (Europe PMC)
- Imazato S, Ikebe K, Nokubi T, Ebisu S, Walls AW. Prevalence of root caries in a selected population of older adults in Japan. J Oral Rehabil 2006-02-01;33(2):137-143. doi:10.1111/j.1365-2842.2006.01547.x · PMID 16457674 · cited by 61 (Europe PMC)
Bibliographic records above were retrieved and verified programmatically from Europe PMC (authors, journal, volume, pages, DOI, PMID, citation count). Coverage, guideline and regulatory statements are quoted from the cited public documents with their dates; verify against the current version before relying on them. This article is not medical or dental advice.